|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 831 |
FusionGeneSummary for ADCY2_ZFP36L2 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: ADCY2_ZFP36L2 | Fusion gene ID: 831 | Hgene | Tgene | Gene symbol | ADCY2 | ZFP36L2 | Gene ID | 108 | 678 |
| Gene name | adenylate cyclase 2 | ZFP36 ring finger protein like 2 | |
| Synonyms | AC2|HBAC2 | BRF2|ERF-2|ERF2|RNF162C|TIS11D | |
| Cytomap | 5p15.31 | 2p21 | |
| Type of gene | protein-coding | protein-coding | |
| Description | adenylate cyclase type 23',5'-cyclic AMP synthetaseATP pyrophosphate-lyase 2adenylate cyclase 2 (brain)adenylate cyclase IIadenylate cyclase type IIadenylyl cyclase 2type II adenylate cyclase | mRNA decay activator protein ZFP36L2EGF-response factor 2TPA-induced sequence 11dZFP36-like 2butyrate response factor 2zinc finger protein 36, C3H type-like 1zinc finger protein 36, C3H type-like 2zinc finger protein 36, C3H1 type-like 2zinc finge | |
| Modification date | 20180522 | 20180523 | |
| UniProtAcc | Q08462 | P47974 | |
| Ensembl transtripts involved in fusion gene | ENST00000338316, ENST00000537121, ENST00000513693, | ENST00000282388, | |
| Fusion gene scores | * DoF score | 20 X 19 X 5=1900 | 4 X 4 X 1=16 |
| # samples | 21 | 4 | |
| ** MAII score | log2(21/1900*10)=-3.17753818555219 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(4/16*10)=1.32192809488736 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
| Context | PubMed: ADCY2 [Title/Abstract] AND ZFP36L2 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | ZFP36L2 | GO:0009611 | response to wounding | 27182009 |
| Tgene | ZFP36L2 | GO:0044344 | cellular response to fibroblast growth factor stimulus | 20166898 |
| Tgene | ZFP36L2 | GO:0070371 | ERK1 and ERK2 cascade | 25106868 |
| Tgene | ZFP36L2 | GO:0071356 | cellular response to tumor necrosis factor | 20166898 |
| Tgene | ZFP36L2 | GO:0071364 | cellular response to epidermal growth factor stimulus | 20166898 |
| Tgene | ZFP36L2 | GO:0071385 | cellular response to glucocorticoid stimulus | 20166898 |
| Tgene | ZFP36L2 | GO:0071560 | cellular response to transforming growth factor beta stimulus | 20166898 |
| Tgene | ZFP36L2 | GO:0097011 | cellular response to granulocyte macrophage colony-stimulating factor stimulus | 20166898 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChiTaRS3.1 | BM995008 | ADCY2 | chr1 | 152005157 | + | ZFP36L2 | chr2 | 43450007 | + |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| intron-3UTR | ENST00000338316 | ENST00000282388 | ADCY2 | chr1 | 152005157 | + | ZFP36L2 | chr2 | 43450007 | + |
| intron-3UTR | ENST00000537121 | ENST00000282388 | ADCY2 | chr1 | 152005157 | + | ZFP36L2 | chr2 | 43450007 | + |
| intron-3UTR | ENST00000513693 | ENST00000282388 | ADCY2 | chr1 | 152005157 | + | ZFP36L2 | chr2 | 43450007 | + |
Top |
FusionProtFeatures for ADCY2_ZFP36L2 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| ADCY2 | ZFP36L2 |
| Catalyzes the formation of the signaling molecule cAMPin response to G-protein signaling (PubMed:15385642). Down-streamsignaling cascades mediate changes in gene expression patterns andlead to increased IL6 production. Functions in signaling cascadesdownstream of the muscarinic acetylcholine receptors (Bysimilarity). {ECO:0000250|UniProtKB:P26769,ECO:0000269|PubMed:15385642}. | Zinc-finger RNA-binding protein that destabilizesseveral cytoplasmic AU-rich element (ARE)-containing mRNAtranscripts by promoting their poly(A) tail removal ordeadenylation, and hence provide a mechanism for attenuatingprotein synthesis (PubMed:25106868, PubMed:14981510). Acts as a3'-untranslated region (UTR) ARE mRNA-binding adapter protein tocommunicate signaling events to the mRNA decay machinery(PubMed:25106868). Functions by recruiting the CCR4-NOTdeadenylase complex and probably other components of thecytoplasmic RNA decay machinery to the bound ARE-containing mRNAs,and hence promotes ARE-mediated mRNA deadenylation and decayprocesses (PubMed:25106868). Binds to 3'-UTR ARE of numerous mRNAs(PubMed:20506496, PubMed:25106868, PubMed:14981510). Promotes ARE-containing mRNA decay of the low-density lipoprotein (LDL)receptor (LDLR) mRNA in response to phorbol 12-myristate 13-acetate (PMA) treatment in a p38 MAPK-dependent manner(PubMed:25106868). Positively regulates early adipogenesis bypromoting ARE-mediated mRNA decay of immediate early genes (IEGs).Plays a role in mature peripheral neuron integrity by promotingARE-containing mRNA decay of the transcriptional repressor RESTmRNA. Plays a role in ovulation and oocyte meiotic maturation bypromoting ARE-mediated mRNA decay of the luteinizing hormonereceptor LHCGR mRNA. Acts as a negative regulator of erythroidcell differentiation: promotes glucocorticoid-induced self-renewalof erythroid cells by binding mRNAs that are induced or highlyexpressed during terminal erythroid differentiation and promotestheir degradation, preventing erythroid cell differentiation. Inassociation with ZFP36L1 maintains quiescence on developing Blymphocytes by promoting ARE-mediated decay of several mRNAsencoding cell cycle regulators that help B cells progress throughthe cell cycle, and hence ensuring accurate variable-diversity-joining (VDJ) recombination process and functional immune cellformation. Together with ZFP36L1 is also necessary for thymocytedevelopment and prevention of T-cell acute lymphoblastic leukemia(T-ALL) transformation by promoting ARE-mediated mRNA decay of theoncogenic transcription factor NOTCH1 mRNA.{ECO:0000250|UniProtKB:P23949, ECO:0000269|PubMed:14981510,ECO:0000269|PubMed:20506496, ECO:0000269|PubMed:25106868}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for ADCY2_ZFP36L2 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for ADCY2_ZFP36L2 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for ADCY2_ZFP36L2 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Hgene | ADCY2 | Q08462 | DB09121 | Aurothioglucose | Adenylate cyclase type 2 | small molecule | approved|withdrawn |
Top |
RelatedDiseases for ADCY2_ZFP36L2 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | ADCY2 | C0004096 | Asthma | 1 | CTD_human |
| Hgene | ADCY2 | C0005586 | Bipolar Disorder | 1 | PSYGENET |
| Tgene | ZFP36L2 | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|